{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:16:18Z","timestamp":1765516578212,"version":"3.48.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the diagnosis and treatment of the condition of T-lymphoblastic lymphoma (T-LBL) transforming into acute myeloid leukemia (AML) following recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of a patient admitted to the First Affiliated Hospital of Henan University of Science and Technology in July 2022 with recurrent T-LBL that progressed to AML. Clinical manifestations, genetic and histopathological findings, and treatment outcomes were evaluated, complemented by a literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The patient, initially diagnosed with T-LBL, achieved complete remission (CR) after combination chemotherapy. Following treatment cessation, the disease recurred and transformed into AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The transformation of T-LBL into AML is exceedingly rare, and the underlying mechanisms of lineage switch remain unclear. Venetoclax combined with chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) may improve prognosis in such cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1673318","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:14:55Z","timestamp":1765516495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Transformation of T-lymphoblastic lymphoma into acute myeloid leukemia after recurrence: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Mengzhuo","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenmiao","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.05.001","article-title":"Chinese expert consensus on the diagnosis and treatment of adult T-lymphoblastic lymphoma (2023 edition)","volume":"44","year":"2023","journal-title":"Chin J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283566","article-title":"Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed\/refractory T-cell acute lymphoblastic leukemia","volume":"108","author":"Aldoss","year":"2023","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2023.100382","article-title":"A case series of therapy-related leukemias: A deadly ricochet","volume":"20","author":"Juthani","year":"2023","journal-title":"Leukemia Res Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.beha.2019.02.008","article-title":"Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks","volume":"32","author":"Al-Juhaishi","year":"2023","journal-title":"Best Pract Res Clin Haematology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.beha.2019.02.013","article-title":"Choosing induction chemotherapy in therapy-related acute myeloid leukemia","volume":"32","author":"Shea","year":"2019","journal-title":"Best Pract Res Clin Haematology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.12.007","article-title":"Treatment strategies for therapy-related acute myeloid leukemia","volume":"20","author":"Dhakal","year":"2020","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-021-01168-x","article-title":"Lymphoblastic lymphoma: a concise review","volume":"24","author":"Intermesoli","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2026","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.09.002","article-title":"Chinese diagnosis and treatment guidelines for recurrent and refractory acute myeloid leukemia (2023 edition)","volume":"44","year":"2023","journal-title":"Chin J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25957","article-title":"Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study","volume":"95","author":"Candoni","year":"2022","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1957876","article-title":"Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series","volume":"62","author":"Wan","year":"2020","journal-title":"Leukemia lymphoma"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy","volume":"98","author":"Zhang","year":"2023","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.01.018","article-title":"Research progress on the treatment of CD30 positive lymphoma with Vibutuximab","volume":"44","author":"Cai","year":"2023","journal-title":"Chin J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1673318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:14:58Z","timestamp":1765516498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1673318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":18,"alternative-id":["10.3389\/fonc.2025.1673318"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1673318","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1673318"}}